Science & Technology
Clinical evaluation of a novel AKT/PDK1 inhibitor, PHT-427, for the treatment of multi-field actinitc keratoses
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R44CA306740-01
Award Ceiling
$2.1M
Award Floor
$2.1M
Close Date
Aug 31, 2026
169 days leftTotal Funding
$2.1M
Expected Awards
1
Posted Date
Sep 15, 2025
Cost Sharing Required
No
Grants.gov ID
sbir-1R44CA306740-01
Description
SBIR Phase Phase II award: "Clinical evaluation of a novel AKT/PDK1 inhibitor, PHT-427, for the treatment of multi-field actinitc keratoses" awarded to PHusis Therapeutics Inc in San Diego, California. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $2,085,765. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses, Women-owned businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.